Compared to warfarin, edoxaban was as effective -- or even more so -- in preventing stroke and blood clots, researchers said.

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

The most common manifestation of pharmacokinetic interactions with warfarin involves the inhibition or induction of its metabolism. Attention should be paid to the relative importance of the ...

“华法林 (Warfarin)”是一种处方血液稀释剂的通用名，该药物于 20 世纪 50 年代上市，经常在电视上观看最新药物广告的人可能会对其感到很熟悉。 这些广告称，这种新型血液稀释剂用于预防中风等重大疾病，服用更方便或副作用更少。 虽然后期的竞争对手一直 ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

In patients with protein C and protein S deficiency, when warfarin therapy is started there is a more rapid fall in concentration of protein C (antigen and activity) than the other vitamin K ...

A phase IIa trial has demonstrated that a structural analogue of warfarin is safe, tolerable, and efficacious. Investigators believe that this new anticoagulant, named tecarfarin, will be ...

Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein ...

Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and ...

Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...